Commercial Genetic Test Validation
Sample Populations: cattle used for validation
- Brahman Sired ARS, Brooksville cattle (344 animals)
* Brahman sires, Brahman dams
- Charolais Sired CMP** cattle (435 animals)
* Charolais sires, Black Angus dams
- Brangus Sired CMP** cattle
* Brangus sires, primarily Brangus and some Brangus cross dams
- Red Angus Sired CMP** cattle
* Red Angus sires, mostly Red Angus dams, some crossbred
- Black Angus Sired CMP** cattle
* Black Angus sires, Black Angus dams
- Australian CRC 1 Indicus-influenced (~ 650 Animals)
* Santa Gertrudis and Belmont Red
- Australian CRC 2 Indicus-influenced (747 animals)
* Brahman, Senepol and Belmont Red infused composites
- Australian CRC 1 Brahmans (~150 Animals)
* Purebred Brahman
- Australian CRC 2 Brahmans (700 animals)
* Purebred Brahman
- Commercial US cattle population (1364 animals)
- * Purebred and crossbred offspring of 285 sires from the following breeds: 202 Angus, 7 Red Angus, 6 Charolais, 7 Gelbveh , 4 Horned Hereford , 11 Polled Hereford, 4 Limousin , 7 Simmental, 1 Braford, 3 Shorthorn, 12 were of mixed breed, and 21 were of unknown breed. Cows were: 360 Angus, 6 Red Angus, 11 Charolais, 2 Horned Hereford , 5 Polled Hereford, 2 Limousin, 9 Simmental, 15 Shorthorn, 598 were crossbred cows, and 356 were of unknown breed composition.
- North American Angus validation population (~760 bulls, steers and heifers)
* Purebred Angus
- North American Bos taurus “Pfizer A***” validation population (~671 bulls, heifers and steers)
* European Maternal Line Composite Bulls, finished on ad lib feed for greater than 40 days, 100 – 130 days on feed
- North American Bos taurus “Pfizer B***” validation population (~785 steers)
* European Maternal Line Composite Steers, 150 – 180 days on feed
- North American Bos indicus-influenced “Pfizer C***” validation population (~395 steers)
* Equal percentage of Simbrah, Red Brangus and Braford maternal line composites.
** CMP = carcass merit project; influential sires in their breed in the 1990s were utilized ("legacy bulls")
*** Letter-designations for validation populations as described in Pfizer Technical Summary (February 2009)